IL308180A - Preparations and methods for use in corona virus and flu - Google Patents

Preparations and methods for use in corona virus and flu

Info

Publication number
IL308180A
IL308180A IL308180A IL30818023A IL308180A IL 308180 A IL308180 A IL 308180A IL 308180 A IL308180 A IL 308180A IL 30818023 A IL30818023 A IL 30818023A IL 308180 A IL308180 A IL 308180A
Authority
IL
Israel
Prior art keywords
coronavirus
methods
influenza compositions
influenza
compositions
Prior art date
Application number
IL308180A
Other languages
English (en)
Hebrew (he)
Inventor
Nita Patel
Bin Zhou
Mimi Guebre-Xabier
Jing-Hui Tian
Alyse D Portnoff
Michael J Massare
Vivek Shinde
Louis Fries
Gale Smith
Original Assignee
Novavax Inc
Nita Patel
Bin Zhou
Guebre Xabier Mimi
Tian jing hui
Alyse D Portnoff
Michael J Massare
Vivek Shinde
Louis Fries
Gale Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc, Nita Patel, Bin Zhou, Guebre Xabier Mimi, Tian jing hui, Alyse D Portnoff, Michael J Massare, Vivek Shinde, Louis Fries, Gale Smith filed Critical Novavax Inc
Publication of IL308180A publication Critical patent/IL308180A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL308180A 2021-05-05 2022-05-03 Preparations and methods for use in corona virus and flu IL308180A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184727P 2021-05-05 2021-05-05
US202163193356P 2021-05-26 2021-05-26
US202163255685P 2021-10-14 2021-10-14
US202263332537P 2022-04-19 2022-04-19
PCT/US2022/027465 WO2022235663A1 (en) 2021-05-05 2022-05-03 Coronavirus and influenza compositions and methods for using them

Publications (1)

Publication Number Publication Date
IL308180A true IL308180A (en) 2024-01-01

Family

ID=83901839

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308180A IL308180A (en) 2021-05-05 2022-05-03 Preparations and methods for use in corona virus and flu

Country Status (11)

Country Link
US (1) US20220354944A1 (enExample)
EP (1) EP4333885A4 (enExample)
JP (1) JP2024516309A (enExample)
KR (1) KR20240024064A (enExample)
AU (1) AU2022270082A1 (enExample)
BR (1) BR112023023035A2 (enExample)
CA (1) CA3217591A1 (enExample)
IL (1) IL308180A (enExample)
MX (1) MX2023013081A (enExample)
TW (1) TW202308685A (enExample)
WO (1) WO2022235663A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal
EP4687968A1 (en) * 2023-04-03 2026-02-11 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
US20250085282A1 (en) * 2023-09-11 2025-03-13 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
US20250144200A1 (en) * 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
EP4670733A1 (en) * 2024-06-27 2025-12-31 Sanofi METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826058C (en) * 2011-02-04 2017-06-06 Zoetis Llc Compositions for canine respiratory disease complex
BR112016006122B1 (pt) * 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230070886A1 (en) * 2020-01-27 2023-03-09 Novavax, Inc. Coronavirus vaccine formulations
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021211749A1 (en) * 2020-04-14 2021-10-21 The Regents Of The University Of California Multi-epitope pan-coronavirus vaccine compositions
GB2596820A (en) * 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
CN112546211A (zh) * 2020-10-23 2021-03-26 嘉晨西海(杭州)生物技术有限公司 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法
CN112480217B (zh) * 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CN113185613B (zh) * 2021-04-13 2022-09-13 武汉大学 新型冠状病毒s蛋白及其亚单位疫苗

Also Published As

Publication number Publication date
BR112023023035A2 (pt) 2024-01-23
EP4333885A1 (en) 2024-03-13
KR20240024064A (ko) 2024-02-23
AU2022270082A1 (en) 2023-11-16
TW202308685A (zh) 2023-03-01
MX2023013081A (es) 2024-01-15
CA3217591A1 (en) 2022-11-10
JP2024516309A (ja) 2024-04-12
WO2022235663A1 (en) 2022-11-10
US20220354944A1 (en) 2022-11-10
EP4333885A4 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
IL308180A (en) Preparations and methods for use in corona virus and flu
GB2594365B (en) Coronavirus vaccine
IL314906B2 (en) Coronavirus vaccine
GB202004974D0 (en) Coronavirus vaccine
ZA202210641B (en) Coronavirus vaccine
IL309175A (en) Methods and preparations for targeting PD-L1
GB202212336D0 (en) Coronavirus vaccine formulations
GB202217951D0 (en) Coronavirus vaccine
GB202004007D0 (en) Coronavirus
PL4208045T3 (pl) Kompozycje i sposoby
IL297070A (en) Vaccine against the corona virus
IL306088A (en) Vaccine formulations against coronavirus
GB202111040D0 (en) Compositions and methods
GB202108585D0 (en) Methods and compositions
IL307625A (en) Compounds and methods for modulating pnpla3 expression
IL318706A (en) Compositions and methods for inducing proptosis
GB202004677D0 (en) Methods and compositions
GB202004755D0 (en) Coronavirus
IL304824A (en) Phosphorofol methods and preparations
GB202116554D0 (en) Methods and compositions
CA3287804A1 (en) Coronavirus and influenza compositions and methods for using them
HK40086268A (en) Coronavirus vaccine compositions and methods
GB202211117D0 (en) Compositions and methods for non-immunogenecity
GB202408093D0 (en) Compositions and methods
GB202214719D0 (en) Compositions and methods